(Total Views: 186)
Posted On: 11/21/2019 8:39:00 AM
Post# of 250663
PBIO's tech has become an essential requirement for our novel workflow in meeting our goals. Gynecologic malignancies include ovarian, uterine, and cervical cancers.
Together they are responsible for approximately 35,000 deaths annually in the United States with ovarian cancer ranking fifth in cancer deaths among women (Aurora Healthcare and the Centers for Disease Control and Prevention). According to Acumen Research and Consulting (2018), the global ovarian cancer diagnostics market alone is forecasted to grow at a CAGR around 5.9% over the forecast time frame and reach around US $1.8 billion by 2026
https://finance.yahoo.com/news/pressure-biosc...00015.html
$PBIO
The new and improved methods to detect these cancers are vitally needed to support the design and development of better treatments through enhanced precision medicine. The IGCS is committed to addressing this critical issue.
Together they are responsible for approximately 35,000 deaths annually in the United States with ovarian cancer ranking fifth in cancer deaths among women (Aurora Healthcare and the Centers for Disease Control and Prevention). According to Acumen Research and Consulting (2018), the global ovarian cancer diagnostics market alone is forecasted to grow at a CAGR around 5.9% over the forecast time frame and reach around US $1.8 billion by 2026
https://finance.yahoo.com/news/pressure-biosc...00015.html
$PBIO
The new and improved methods to detect these cancers are vitally needed to support the design and development of better treatments through enhanced precision medicine. The IGCS is committed to addressing this critical issue.
(0)
(0)
